KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Current Liabilities: 2013-2025

Historic Total Current Liabilities for Xenon Pharmaceuticals (XENE) over the last 10 years, with Sep 2025 value amounting to $38.3 million.

  • Xenon Pharmaceuticals' Total Current Liabilities rose 29.10% to $38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.3 million, marking a year-over-year increase of 29.10%. This contributed to the annual value of $35.6 million for FY2024, which is 30.50% up from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Total Current Liabilities is $38.3 million, which was up 16.00% from $33.0 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Total Current Liabilities registered a high of $38.3 million during Q3 2025, and its lowest value of $8.0 million during Q1 2022.
  • In the last 3 years, Xenon Pharmaceuticals' Total Current Liabilities had a median value of $29.7 million in 2024 and averaged $29.5 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first tumbled by 76.32% in 2021, then skyrocketed by 181.77% in 2023.
  • Xenon Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $14.3 million in 2021, then skyrocketed by 58.51% to $22.7 million in 2022, then climbed by 20.13% to $27.3 million in 2023, then surged by 30.50% to $35.6 million in 2024, then climbed by 29.10% to $38.3 million in 2025.
  • Its last three reported values are $38.3 million in Q3 2025, $33.0 million for Q2 2025, and $32.0 million during Q1 2025.